Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.
Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Beitinjaneh AM, et al. Among authors: hosing c. Leuk Lymphoma. 2012 Aug;53(8):1525-9. doi: 10.3109/10428194.2012.656635. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22242817
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Shah N, et al. Among authors: hosing cm. Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27. Leukemia. 2015. PMID: 25721897 Free PMC article. Clinical Trial. No abstract available.
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Kongtim P, et al. Among authors: hosing cm. Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12. Leukemia. 2017. PMID: 28400618 Free PMC article. No abstract available.
Umbilical cord blood graft engineering: challenges and opportunities.
Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Thompson PA, et al. Among authors: hosing cm. Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S55-62. doi: 10.1038/bmt.2015.97. Bone Marrow Transplant. 2015. PMID: 26039209 Review.
Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: identifying disease risk factors for toxicity and long-term outcomes in a prospective, single-arm trial.
Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Georges GE, et al. Among authors: hosing c. Arthritis Rheumatol. 2024 Dec 3. doi: 10.1002/art.43072. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39624016
Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplantation and Cellular Therapy 29/3 (2023) 204-204].
Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Alkhunaizi M, et al. Among authors: hosing c. Transplant Cell Ther. 2024 Nov 17:S2666-6367(24)00742-5. doi: 10.1016/j.jtct.2024.10.013. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39561968 No abstract available.
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Ramdial J, et al. Among authors: hosing c. Bone Marrow Transplant. 2024 Dec;59(12):1754-1762. doi: 10.1038/s41409-024-02394-0. Epub 2024 Sep 28. Bone Marrow Transplant. 2024. PMID: 39341929 Free PMC article.
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study.
Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ. Angelidakis G, et al. Among authors: hosing c. Vaccines (Basel). 2024 Sep 19;12(9):1070. doi: 10.3390/vaccines12091070. Vaccines (Basel). 2024. PMID: 39340100 Free PMC article.
308 results